sefulness of nasal pressure monitor for sedation in invasive endoscopic procedure:A randomized controlled trial - UNSTOP trial

Kato Naoya0 sites269 target enrollmentStarted: November 29, 2019Last updated: October 17, 2023

Trial Snapshot

No summary available.

•We include patients undergoing invasive endoscopic procedure (ERCP,ESD,EUS-FNA,DBE) under sedation.
•1)Ages 20 and older (any gender)
•2)Patients with written consent after receiving sufficient explanation for this study. The consent is based on free will.
•3)Percutaneous oxygen saturation(SPO2) 95% or more in room air.
•4)Systolic blood pressure 90mmHg or more

•Patients who fall under any of the following criteria, will be excluded from the study.
•1)Patients who usually use opioid or benzodiazepine not for sleeping drug.
•2)Patients who have been enrolled another clinical trial within 4 weeks of registry of this trial.
•3)Patients who abuse drugs or is considered too terrible condition of physical, mental or circumstance for enrollment or evaluation.
•4)Patients who have any cardiac disorder of the following.
•a)Heart failure of NYHA class 3 or higher.
•b)Coronary artery disease with symptoms. History of myocardial infarction within 24 weeks prior to enrollment.
•c)Arrhythmias requiring control with antiarrhythmic drugs such as beta blocker and digoxin (CTCAE version 4.0 Grade 3 or higher).
•d)Poor control hypertension.
•5)Bradycardia (heart rate less than 50/min)
•6)American Society of Anesthesiologists (ASA) physical status classification 4 or more
•7)Patients with severe thyroid disease.
•8)Pregnant or lactating woman; woman of child bearing age unless using effective contraception (In case of suspected pregnancy, pregnancy test should be conducted)
•9)Possibility of allergic reaction to propofol or fentanyl.
•10)Any condition that in the opinion of the investigators could impair the patient's safety or make the study difficult to comply with the protocol by participating in the study.

Sponsor